PDE5A
ENSG00000138735
Target class
Enzyme
Chromosome
4
Approved drugs
7
Clinical candidates (approved and in development)
11
- Approved drugs
- 7
- Clinical candidates (approved and in development)
- 11
- Chemical probe available
- Yes
- Target name
- PDE5A
- Gene name
- Phosphodiesterase 5A
- Gene symbol
- PDE5A
- Protein name
- cGMP-specific 3',5'-cyclic phosphodiesterase (EC 3.1.4.35) (cGMP-binding cGMP-specific phosphodiesterase) (CGB-PDE)
- Gene biotype
- Protein coding
- Gene family
- Phosphodiesterases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 81.89
- Tissue specificity (Gini)
- 0.644
- Tissue specificity (tau)
- 0.852
- KEGG gene identifiers
- hsa:8654
- Protein interaction confidence
- 0.822441
- Protein interaction partners
- 34
- R-HSA-418457
- R-HSA-445355
- R-HSA-9013422
- End position
- 119628804
- Start position
- 119494397
- Chromosome
- 4
- Strand
- Reverse
- Basal body
- Cytosol
- Tissue specificity (tau)
- 0.851649
- Expression inequality (Gini)
- 0.644473
Expression in transcripts per million
- Artery - Aorta
- 81.89
- Artery - Tibial
- 67.07
- Esophagus - Muscularis
- 57.57
- Esophagus - Gastroesophageal Junction
- 55.83
- Colon - Sigmoid
- 49.22
Expression in transcripts per million
- Artery - Aorta81.89
- Artery - Tibial67.07
- Esophagus - Muscularis57.57
- Esophagus - Gastroesophageal Junction55.83
- Colon - Sigmoid49.22
- Artery - Coronary44.62
- Cervix - Ectocervix43.93
- Cervix - Endocervix26.65
- Prostate26.65
- Fallopian Tube22.39
- Nerve - Tibial19.34
- Vagina19.29
- Lung18.91
- Adipose - Subcutaneous18.44
- Colon - Transverse17.42
- Bladder16.01
- Thyroid15.66
- Breast - Mammary Tissue11.98
- Uterus11.3
- Small Intestine - Terminal Ileum8.71
- Adipose - Visceral (Omentum)7.95
- Testis7.19
- Skin - Sun Exposed (Lower leg)5.57
- Ovary5.43
- Minor Salivary Gland4.76
And 29 more, listed on the interactive page.
Cellular components
- GO:0005829
- GO:0005515
- GO:0030553
- GO:0047555
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hPDE5, is one of one assay component(s) measured or calculated from the NVS_ENZ_hPDE5 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (1,012)
- "As Required" Oral Sildenafil in Raynaud's Phenomenon
- "Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
- A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
- A Bioavailability Study of LY2452473 and Tadalafil
- A Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form
- A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
- A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
- A Comparative Pharmacokinetic and Pharmacodynamic Study of Sildenafil in Adult Smokers and Non Smokers
- A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
- A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
- A Double-blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction
- A Extension Study of Udenafil in Adolescents
- A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
- A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
- A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes
- A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction.
- A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate
- A Multicentre, Prospective, Open-label, Non-comparative Study
Drugs (13)
- Avanafil Phosphodiesterase 5A inhibitor
- Dipyridamole 3',5'-cyclic phosphodiesterase inhibitor
- Gisadenafil Phosphodiesterase 5A inhibitor
- Ibudilast Phosphodiesterase 5A inhibitor
- Pentoxifylline 3',5'-cyclic phosphodiesterase inhibitor
- PF-00489791 Phosphodiesterase 5A inhibitor
- PF-03049423 Phosphodiesterase 5A inhibitor
- Sildenafil Phosphodiesterase 5A inhibitor
- Sildenafil citrate Phosphodiesterase 5A inhibitor
- Tadalafil Phosphodiesterase 5A inhibitor
- Udenafil Phosphodiesterase 5A inhibitor
- Vardenafil Phosphodiesterase 5A inhibitor
- Vardenafil hydrochloride Phosphodiesterase 5A inhibitor